WHO公布 2024-2025 年度北半球流感疫苗推荐毒株

清風徐来

The WHO recommends that trivalent vaccines for use in the 2024-2025 northern hemisphere influenza season contain the following:

Egg-based vaccines

an A/Victoria/4897/2022 (H1N1)pdm09-like virus;

an A/Thailand/8/2022 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

Cell culture- or recombinant-based vaccines

an A/Wisconsin/67/2022 (H1N1)pdm09-like virus;

an A/Massachusetts/18/2022 (H3N2)-like virus; and

a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.

For quadrivalent egg- or cell culture-based or recombinant vaccines for use in the 2024-2025 northern hemisphere influenza season, the WHO recommends inclusion of the following as the B/Yamagata lineage component:

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.

椒陵小小兵

又要重新构建菌种了

清風徐来

椒陵小小兵 发表于 2024-2-23 20:48
又要重新构建菌种了

与南半球推荐毒株一致。应该很多企业都已经买完了。

轩云溪

清風徐来 发表于 2024-2-23 21:10
与南半球推荐毒株一致。应该很多企业都已经买完了。

现在做流感疫苗的企业是不是越来越多了

清風徐来

轩云溪 发表于 2024-2-27 14:54
现在做流感疫苗的企业是不是越来越多了

三四价流感有文号的应该有16家（包含台湾省国光生物），正在报上市申请的好像有三家，还有好多个在研的如，成大、欧琳、康泰、沃森、培森等等。竞争还是蛮激烈的，但国内的流感疫苗接种率偏低，市场空间还是很大的。